	Evaluation indicators for bladder dysfunction in Chinese patients following cervical cancer surgery: a Delphi study based on nursing outcomes classification. BMC Cancer Han X, Di R, Zhang H, Zhou B. PMID: 41454233 [PubMed - as supplied by publisher]
	Neoadjuvant pamiparib plus abiraterone and androgen deprivation therapy for high-risk/very high-risk localized prostate cancer: an open-label, single-arm, phase 2 study. Prostate Cancer Prostatic Dis Gong T, Liang S, Wu Z, Qiu X, Xu L, Peng S, Guo H, Zhang S, Zhuang J. PMID: 41454188 [PubMed - as supplied by publisher]
	Efficacy and safety of tislelizumab combined with chemotherapy for locally advanced penile cancer: a prospective, single-arm clinical study. Br J Cancer Shan X, Bai H, Ning H, Xie C, Chen Y, Xing S, Ni D, Guo X, Zeng J, Hu L. PMID: 41454186 [PubMed - as supplied by publisher]
	Barriers and facilitators to prostate cancer healthcare in Black men in the UK: from diagnosis to survivorship. J Cancer Surviv Ettehad D, Mohammed H, Bailey JV, Schloss D, Walters K, Merriel SWD, Kinnaird W, Shaw G, Kirby M, Gopal DP, Huang Q, Baker H, Plackett R, Schartau P. PMID: 41454095 [PubMed - as supplied by publisher]
	Optimised comorbidity indices can reflect patient performance status in register based studies of prostate cancer. Sci Rep Westerberg M, Garmo H, Bonnedahl J, Eriksson MH, Robinson D, Stattin P, Gedeborg R. PMID: 41453947 [PubMed - as supplied by publisher]
	The value of PSMA PET for risk stratification in prostate cancer: an update and future aspects. Semin Nucl Med Civan C, Karpinski MJ, Rahbar K, Fendler WP, Herrmann K. PMID: 41453817 [PubMed - as supplied by publisher]
	Study design and methodologies for the men moving forward lifestyle intervention trial with black prostate cancer survivors. Contemp Clin Trials Awoyinka I, Stolley MR, Papanek P, Flynn KE, Bylow K, Kilari D, Gann P, Banerjee A, Sheean P. PMID: 41453520 [PubMed - as supplied by publisher]
	Tolerability of docetaxel in octogenarians with metastatic prostate cancer in the triplet therapy era: A single-center retrospective cohort study. J Geriatr Oncol Usui K, Suzuki A, Kubo H, Matsumoto T, Aigase T, Kishida T, Nakaigawa N. PMID: 41453269 [PubMed - as supplied by publisher]
	Immunotherapy Rechallenge in Metastatic Renal Cell Carcinoma: A Meta-Analysis of Randomized Clinical Trials. Oncologist Bolek H, Yazgan SC, Yekedüz E, McGregor BA, McKay RR, Pal SK, Choueiri TK, Ürün Y. PMID: 41452751 [PubMed - as supplied by publisher]
	Selective by design: early adoption patterns of single-port off-clamp robotic partial nephrectomy in a high-volume center. J Robot Surg Anceschi U, Basile S, Tuderti G, Brassetti A, Mastroianni R, Bologna E, Licari LC, Flammia RS, Bove AM, Ferriero M, Proietti F, Guaglianone S, Leonardo C, Simone G. PMID: 41452433 [PubMed - indexed for MEDLINE]
	HIF-2Î± inhibitors in clear cell renal cell carcinoma: a clinical pharmacy perspective on lipid metabolism, therapeutic management, and resistance strategies. Front Med (Lausanne) Chen D, Hua C. PMID: 41451091 [PubMed]
	Correction: TET2 gene mutation status associated with poor prognosis of transition zone prostate cancer: a retrospective cohort study based on whole exome sequencing and machine learning models. Front Endocrinol (Lausanne) Wang Y, Yu A, Gao Z, Yuan X, Du X, Shi P, Guan H, Wen S, Wang H, Wang L, Fan B, Liu Z. PMID: 41450576 [PubMed - in process]
	Community Understanding and Attitudes Toward Prostate-Specific Antigen (PSA) Testing for Prostate Cancer Screening: A Cross-Sectional Survey Study From Saudi Arabia. Cureus Alkhars AF, Almaghlouth AK, Almusalem NF, Alaboud MS, Alshafei AB, Al Janobi MS, Al Watyan HA, Alramadhan HM, Alramadhan HA. PMID: 41450362 [PubMed]
	Clinical efficacy of apalutamide in Asian patients with metastatic castration-sensitive prostate cancer: Bayesian reanalysis of the TITAN trial. Jpn J Clin Oncol Chen W, Yoshida S, Hirakawa A, Sato H, Yajima S, Kobayashi M, Fujiwara M, Fukushima H, Arita Y, Waseda Y, Tanaka H, Masuda H, Fujii Y. PMID: 41450247 [PubMed - as supplied by publisher]
	Effects of Prior Local Therapy by Radical Prostatectomy or Radiotherapy on the Efficacy and Quality of Life of Patients Treated With Darolutamide in ARAMIS. Cancer Med Saar M, Fizazi K, Shore ND, Smith M, Damber JE, Semenov A, Ribal MJ, Birtle A, Rigaud J, Wallis CJD, Grimm MO, Halabi S, Armstrong AJ, Mohamed AF, Adorjan P, Srinivasan S, Verholen F, Morgans AK, Siemens DR. PMID: 41450200 [PubMed - indexed for MEDLINE]
	Predictive Factors for Gastrointestinal and Hepatic Adverse Events During 5-Aminolevulinic Acid-Guided Photodynamic Diagnosis in Bladder Cancer: Exploratory Analysis of the Phase III SPP2C102 Trial. Int J Urol Taoka R, Fukuhara H, Miyake M, Kobayashi K, Ikeda A, Kanao K, Komai Y, Fujiwara R, Sato Y, Sugimoto M, Tsuzuki T, Fujimoto K, Inoue K, Oya M. PMID: 41449791 [PubMed - as supplied by publisher]
	Real-world efficacy of switching androgen receptor signaling inhibitor therapy following apalutamide discontinuation because of adverse events in advanced prostate cancer: a multicenter study. Jpn J Clin Oncol Tohi Y, Kato T, Fujiwara K, Hayashida Y, Matsuoka Y, Hirama H, Yano T, Tsunemori H, Arai H, Nomura I, Yamaoka N, Mashima T, Kohashiguchi K, Abe Y, Naito H, Okazoe H, Taoka R, Ueda N, Sugimoto M. PMID: 41449570 [PubMed - as supplied by publisher]
	Evaluation of INR101, a PSMA-Targeted (18)F PET Tracer, for suspected prostate cancer: A multicenter phase I/IIa trial with histopathologic confirmation. EJNMMI Res Yang J, Wan W, Zhang J, Zhang N, Yang X, Wang W, Ma H, Xu Y, Fu Z, Wang X, Liu Y, Wang M, Liu F, Guo Y, Liu Y, Zhang X. PMID: 41449298 [PubMed - as supplied by publisher]
	Prostate cancer diagnosis using sensitive and sophisticated machine learning classifiers based on non-invasive urinary RNA biomarkers (PCASSO). Sci Rep Goh H, Heo T, Kim J, Kim Y, Lim B, Woo MK, Choi KY, Kim CS, Kim J. PMID: 41449174 [PubMed - as supplied by publisher]
	Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial. Lancet Oncol Fizazi K, Saad F, Alonso-Gordoa T, , Barthélémy P, Voog E, Javier Cutuli H, Buchler T, Ye D, Castellano D, Kwiatkowski M, Arslan C, Richardet M, Alifrangis C, Goh JC, Vianna K, Han W, Hatano K, Todenhöfer T, Retz M, Srivastava A, Jin C, Gupta S, Trandafirescu G, Campos A, Lee CW, van Kooten Losio M, Subudhi SK. PMID: 41449150 [PubMed - indexed for MEDLINE]

Articles 1 - 20 / 174816

Page 1 of 8741



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy